The Metro Nashville Public Health TB Program has enrolled its first patients into a new clinical trial for latent TB infection. This trial is led by Dr. Timothy Sterling with funding from the Centers for Disease Control and Prevention (CDC) through the Tuberculosis Trials Consortium (TBTC). The Vanderbilt TB Center and Metro Nashville TB staff have worked tirelessly to fulfill the regulatory requirements and finalize protocols in order to begin a clinical trial and we applaud their efforts with these first enrollments!
Study 37 ASTERoiD (Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine given Daily for LTBI) will evaluate a new regimen for treatment of latent TB infection: six weeks of daily rifapentine. It will be compared against a 12-16 week rifamycin-based treatment of latent M. tuberculosis infection, chosen by the enrolling site. This trial will assess the regimen for safety, tolerability and effectiveness.
Special thanks to Alicia Wright, Amy Kerrigan, Kristian Atchley, Diedra Freeman, Billy Reagon, Johanna Shaw-KaiKai, and the entire Metro Public Health TB staff for all their hard work to begin this trial.